In synthesis, these first different trials showed an improved OS and PFS in unresectable stage III NSCLC patients treated with Durvalumab after CRT, especially if the tumor is adenocarcinoma at earlier stages, if the PD-L1 is positive and if the CRT is concurrent over sequential chemo-radiotherapy. This evidence concerns the gene CD274 and neoplasm.